Low-dose naltrexone: Finnish chart review
Polo O, Pesonen P, Tuominen E · 2019 · Fatigue: Biomedicine, Health & Behavior
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Retrospective review of clinical records from 2010–2014. Patients used low-dose naltrexone; the paper describes 3–4.5 mg/day as the typical range.
Dose, route and schedule
Retrospective review of clinical records from 2010–2014. Patients used low-dose naltrexone; the paper describes 3–4.5 mg/day as the typical range.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported response | 73.9% reported improvement in at least one symptom. | |
| Specific symptoms | Physical performance improved in 23.9% and cognitive symptoms in 21.1% by chart review. | |
| Reported adverse effects | The paper describes temporary insomnia, unusual dreams and headache. |
Uncontrolled, retrospective reports cannot establish a treatment effect. An October 2026 post-COVID randomized preprint tested a different cohort.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Uncontrolled, retrospective reports cannot establish a treatment effect. An October 2026 post-COVID randomized preprint tested a different cohort.
Source access
Retrospective review of clinical records from 2010–2014. Patients used low-dose naltrexone; the paper describes 3–4.5 mg/day as the typical range.
Source reviewed 2026-11-12.
Citation and original source
Original source: Polo O, Pesonen P, Tuominen E. Low-dose naltrexone: Finnish chart review Fatigue: Biomedicine, Health & Behavior 2019.
Molekul research summary: https://molekul.io/research/naltrexone-polo-2019. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry